Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.44 |
| ▸ | ULK1 | O75385 | 7/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857220 | 1.00 | RIPK1 (0.44) | RIPK1ULK1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL26857218 | 1.00 | RIPK1 (0.44) | RIPK1ULK1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL26857333 | 0.91 | PIK3CG (0.42) | RIPK1PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL26857216 | 0.91 | ULK1 (0.45) | RIPK1ULK1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL26857349 | 0.91 | PIK3CD (0.44) | RIPK1PIK3CDPIK3CAPIK3CGPDE2A | |
| SCHEMBL26857261 | 0.90 | MMP12 (0.47) | RIPK1PIK3CDPIK3CAPIK3CGPHGDH | |
| SCHEMBL26857266 | 0.90 | MMP12 (0.47) | RIPK1PIK3CDPIK3CAPIK3CGPHGDH | |
| SCHEMBL26857341 | 0.90 | PDE2A (0.45) | RIPK1PIK3CDPIK3CAPIK3CGPDE2A | |
| SCHEMBL26857329 | 0.89 | PDE2A (0.41) | RIPK1PIK3CDPIK3CAPIK3CGPDE2A | |
| SCHEMBL26857344 | 0.89 | CLK1 (0.45) | RIPK1PIK3CDPIK3CAPIK3CGPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PARK7 | RIPK1 2428/4885ULK1 172/4885PIK3CD 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.